Medical Pharmacology: Chapter 7: Hypertension — Clinical and Pharmacological Series -- Module: HTN-03 — First-Line Antihypertensive Drug Classes: Mechanisms, Selection, and Contraindications

Chapter 7: Hypertension — Clinical and Pharmacological Series — Module: HTN-03 — First-Line Antihypertensive Drug Classes: Mechanisms, Selection, and Contraindications
Tier: Tier 2

1. A 69-year-old man with hypertension, HFrEF (EF 28%), and newly diagnosed moderate persistent asthma is being evaluated for optimal antihypertensive and heart failure therapy. He has never been on a beta-blocker. His cardiologist wants to start one for HFrEF mortality benefit. His pulmonologist is concerned about bronchospasm. Which of the following most accurately describes how to reconcile these competing considerations?

A) Beta-blockers are absolutely contraindicated in any patient with asthma regardless of the indication — the mortality benefit in HFrEF does not outweigh the risk of fatal bronchospasm and an alternative must always be found
B) A cardioselective beta-1 blocker such as carvedilol should be initiated at standard doses — carvedilol's combined alpha and beta blockade eliminates the bronchospasm risk because the alpha-1 blockade causes bronchodilation that counteracts any beta-2 mediated bronchoconstriction
C) A cardioselective beta-1 blocker (bisoprolol or metoprolol succinate) can be cautiously initiated at a very low dose in a patient with stable, well-controlled asthma when the indication is compelling such as HFrEF — cardioselective agents have significantly less beta-2 blockade than non-selective agents; the risk of bronchospasm is real but manageable with careful monitoring; this should be done in close coordination with the pulmonologist with baseline spirometry and slow titration; the mortality benefit of beta-blockers in HFrEF is substantial and the risk-benefit calculation often favors cautious use
D) The HFrEF should be treated with verapamil instead of a beta-blocker — non-dihydropyridine CCBs provide equivalent mortality benefit in HFrEF without any pulmonary risk
E) Nebivolol should be initiated at full dose immediately — its nitric oxide-mediated vasodilation causes direct bronchodilation that makes it completely safe in any severity of asthma

ANSWER: C

Rationale:

This is a classic competing indication scenario — HFrEF carries a compelling indication for beta-blockers with proven mortality benefit (MERIT-HF, COPERNICUS, CIBIS-II); asthma is a relative, not absolute, contraindication to beta-blockers; cardioselective beta-1 blockers (bisoprolol, metoprolol succinate) have significantly less beta-2 receptor blockade than non-selective agents and can be used cautiously in stable, well-controlled asthma; the approach is low starting dose, slow titration, baseline spirometry, close pulmonologist coordination, and patient education about worsening respiratory symptoms; in severe or poorly controlled asthma the risk-benefit may not favor this approach, but in moderate stable asthma with compelling HFrEF indication, cautious use is often appropriate.

Option A: Option A is incorrect — asthma is a relative contraindication, not absolute; in compelling indications such as HFrEF the risk-benefit often favors cautious use of cardioselective agents.
Option B: Option B is incorrect — carvedilol is a non-selective beta-blocker with additional alpha-1 blockade; the alpha-1 blockade does not counteract beta-2 mediated bronchoconstriction and carvedilol is actually the beta-blocker with greatest bronchospasm risk in this population.
Option D: Option D is incorrect — verapamil is specifically contraindicated in HFrEF due to significant negative inotropic effects; it does not provide equivalent mortality benefit and would worsen the cardiomyopathy.
Option E: Option E is incorrect — while nebivolol's NO-mediated vasodilation reduces peripheral vascular resistance, it does not cause direct bronchodilation sufficient to make it completely safe in any severity of asthma; starting at full dose without titration in a new beta-blocker user with asthma is inappropriate.

2. A 74-year-old woman with hypertension and stage 3b CKD (eGFR 38 mL/min/1.73m²) has BP of 158/92 mmHg. Her potassium is 5.1 mEq/L. Her physician wants to add RAAS inhibition for BP control. Which of the following most accurately describes the approach?

A) ACE inhibitors and ARBs are absolutely contraindicated in any patient with eGFR below 45 mL/min — the risk of acute kidney injury and hyperkalemia makes RAAS inhibition uniformly unsafe below this threshold
B) An ACE inhibitor or ARB can be initiated cautiously with close monitoring — CKD is not an absolute contraindication to RAAS inhibition; in fact RAAS inhibition slows CKD progression particularly with proteinuria; however her potassium of 5.1 mEq/L is already borderline elevated and warrants caution; starting at a low dose with potassium and creatinine recheck in 1–2 weeks is appropriate; dietary potassium counseling and possible addition of a kaliuretic agent may be needed; if potassium rises above 5.5–6.0 mEq/L the dose should be reduced or a potassium binder initiated to allow continuation
C) Combining an ACE inhibitor and ARB provides superior renoprotection in CKD and both should be started simultaneously to maximize RAAS blockade before the eGFR declines further
D) Spironolactone is preferred over ACE inhibitors or ARBs in stage 3b CKD because it provides renoprotection without causing the creatinine rise associated with efferent arteriolar dilation
E) The potassium of 5.1 mEq/L is a definitive contraindication to any RAAS inhibition in this patient — no dose, monitoring strategy, or adjunct therapy can make RAAS blockade safe at this potassium level with this eGFR

ANSWER: B

Rationale:

CKD is not an absolute contraindication to RAAS inhibition — in fact ACE inhibitors and ARBs slow CKD progression, particularly in patients with proteinuria, making them preferred antihypertensives in CKD when tolerated; her potassium of 5.1 mEq/L is borderline and warrants caution but is not a definitive contraindication; the approach is low starting dose, close monitoring of potassium and creatinine at 1–2 weeks, dietary potassium counseling (avoiding high-potassium foods), and consideration of a kaliuretic diuretic or potassium binder if potassium rises; RAAS inhibition should be discontinued or dose-reduced if potassium exceeds 5.5–6.0 mEq/L or creatinine rises more than 30–35% above baseline.

Option A: Option A is incorrect — eGFR below 45 mL/min is not an absolute contraindication to RAAS inhibition; many CKD guidelines specifically recommend RAAS inhibition in CKD with albuminuria regardless of eGFR down to approximately 15–20 mL/min with appropriate monitoring.
Option C: Option C is incorrect — dual RAAS blockade with combined ACE inhibitor and ARB is not recommended; the ONTARGET trial demonstrated that dual blockade increased adverse events (hypotension, hyperkalemia, AKI) without additional cardiovascular benefit compared to monotherapy.
Option D: Option D is incorrect — spironolactone carries higher hyperkalemia risk than ACE inhibitors or ARBs in CKD stage 3b; it is not preferred over RAAS inhibition in this setting.
Option E: Option E is incorrect — potassium of 5.1 mEq/L with careful monitoring, dietary counseling, and adjunctive therapy is manageable; it is not a definitive contraindication to all RAAS inhibition.

3. A 55-year-old man with hypertension, type 2 diabetes, and gout (two attacks in the past year, currently managed with allopurinol) has BP of 162/98 mmHg. His physician wants to initiate antihypertensive therapy. Which of the following represents the most pharmacologically rational drug selection considering all three conditions?

A) Chlorthalidone — thiazide diuretics are the preferred first-line agent in diabetes and the uricosuric effect will reduce his uric acid burden even further when combined with allopurinol
B) Losartan — as an ARB it addresses hypertension, has a mild uricosuric effect through URAT1 inhibition that complements his allopurinol therapy and reduces gout risk compared to other antihypertensives, and RAAS inhibition is beneficial in diabetic patients; its uricosuric property is unique among ARBs
C) Metoprolol succinate — beta-1 selective blockade avoids the metabolic effects of non-selective agents and has no effect on uric acid metabolism making it safe in gout
D) Amlodipine — dihydropyridine CCBs have no effect on uric acid and no interaction with allopurinol making them the safest choice in gout
E) Hydrochlorothiazide — the shorter half-life compared to chlorthalidone means less sustained uric acid elevation and is safer than chlorthalidone in a patient with active gout

ANSWER: B

Rationale:

Losartan is the most pharmacologically rational choice here — it addresses hypertension through AT1 receptor blockade; among ARBs it has a unique mild uricosuric effect through inhibition of URAT1 (the urate reabsorption transporter in the proximal tubule) which complements allopurinol and actively reduces serum urate, making it the preferred antihypertensive in patients with gout or hyperuricemia; RAAS inhibition also provides cardiovascular and potential renal benefit in diabetes; this is a three-way pharmacological fit.

Option A: Option A is incorrect — thiazides raise uric acid levels through volume contraction and competition for organic anion secretion; they would worsen his gout risk despite allopurinol co-therapy; they are not the preferred choice in a patient with active gout.
Option C: Option C is incorrect — while metoprolol is safe in gout (no uric acid effect), it does not provide the uricosuric benefit of losartan and is not preferred over RAAS inhibition in a diabetic patient; it is pharmacologically neutral but not optimal.
Option D: Option D is incorrect — amlodipine is also safe in gout but similarly lacks the uricosuric benefit of losartan; in a patient where pharmacological synergy is achievable, neutral is inferior to beneficial.
Option E: Option E is incorrect — both hydrochlorothiazide and chlorthalidone raise uric acid through the same NCC blockade mechanism; the shorter half-life of HCTZ does not meaningfully reduce uric acid elevation or gout risk; both are relatively contraindicated in active gout.

4. A 60-year-old woman with hypertension is on lisinopril 40 mg and chlorthalidone 25 mg. Her BP is 148/90 mmHg. She has no diabetes, no CKD, no HF, no prior MI. Potassium is 3.7 mEq/L. Her physician considers adding spironolactone 25 mg as a third agent. Which of the following most accurately evaluates this decision?

A) Spironolactone is an appropriate third agent — the PATHWAY-2 trial demonstrated that spironolactone was superior to placebo, doxazosin, and bisoprolol as add-on therapy in resistant hypertension; however this patient is on only two agents and does not yet meet the definition of resistant hypertension (uncontrolled BP on three maximally tolerated agents including a diuretic); before adding spironolactone the amlodipine addition completing the standard ACE+CCB+thiazide triple should be considered first; if BP remains uncontrolled on three agents, spironolactone would then be the evidence-based fourth agent
B) Spironolactone is contraindicated as a third agent because combining it with an ACE inhibitor will cause fatal hyperkalemia in all patients regardless of baseline potassium or renal function
C) Spironolactone should be added immediately — it is always superior to CCBs as a third agent because unrecognized primary aldosteronism underlies all cases of treatment-resistant hypertension
D) Spironolactone and chlorthalidone together are contraindicated — combining two diuretics causes severe volume depletion that is uniformly dangerous
E) Spironolactone is the correct third agent — the ACCOMPLISH trial demonstrated that ACE inhibitor plus spironolactone plus thiazide is the superior three-drug combination for cardiovascular outcomes

ANSWER: A

Rationale:

The pharmacological reasoning here requires distinguishing between resistant hypertension (uncontrolled on three maximally dosed agents including a diuretic) and difficult-to-control hypertension on two agents — this patient is on two agents and has not yet tried the standard three-drug combination; the logical next step before reaching for spironolactone is to complete the ACE inhibitor plus CCB plus thiazide triple by adding amlodipine; the PATHWAY-2 trial established spironolactone as the superior fourth agent in true resistant hypertension; her potassium of 3.7 mEq/L and absence of advanced CKD make spironolactone safe if eventually indicated, but sequencing matters — three-drug therapy should precede four-drug therapy.

Option B: Option B is incorrect — spironolactone combined with an ACE inhibitor does increase hyperkalemia risk and requires monitoring, but it does not cause fatal hyperkalemia in all patients regardless of renal function; with appropriate monitoring and normal renal function it is used safely.
Option C: Option C is incorrect — primary aldosteronism is not the universal cause of treatment resistance; empirical spironolactone without biochemical PA screening is not guideline-recommended for all resistant hypertensives.
Option D: Option D is incorrect — combining spironolactone (a potassium-sparing diuretic) with chlorthalidone (a thiazide) is common clinical practice; the two agents have complementary mechanisms and the thiazide-induced hypokalemia is often offset by the spironolactone; severe volume depletion is not an expected consequence of this combination at standard doses.
Option E: Option E is incorrect — the ACCOMPLISH trial compared ACE inhibitor plus CCB versus ACE inhibitor plus HCTZ; it did not study spironolactone as a third agent; attributing this finding to ACCOMPLISH is factually incorrect.

5. A 52-year-old man with hypertension is started on hydrochlorothiazide 25 mg. At 6-week follow-up his BP is well controlled at 128/76 mmHg but his fasting glucose has risen from 98 to 118 mg/dL and his LDL has risen from 108 to 128 mg/dL. He asks whether his blood pressure medication could be responsible. Which of the following most accurately addresses his question?

A) Thiazide diuretics have no metabolic effects — the glucose and lipid changes are coincidental and unrelated to the hydrochlorothiazide; dietary changes or a new illness should be sought as the cause
B) The LDL rise is caused by hydrochlorothiazide-induced inhibition of HMG-CoA reductase — thiazides block the same enzyme as statins but in reverse, stimulating cholesterol synthesis in the liver
C) The glucose rise is caused by hydrochlorothiazide-induced glucosuria — the drug blocks glucose reabsorption in the proximal tubule causing urinary glucose loss that paradoxically raises fasting plasma glucose through a compensatory hepatic glucose release mechanism
D) Thiazide diuretics can worsen glucose tolerance and raise LDL cholesterol through established mechanisms — hypokalemia from thiazide use impairs insulin secretion from pancreatic beta cells (potassium-dependent membrane depolarization is required for insulin release); thiazides also have direct effects on hepatic lipid metabolism raising LDL and triglycerides; these metabolic effects are dose-dependent and more pronounced at higher doses; switching to chlorthalidone at a lower dose (12.5 mg), adding potassium supplementation, or switching to a metabolically neutral antihypertensive class should be considered
E) These metabolic effects are permanent and irreversible — once thiazide-induced glucose intolerance and dyslipidemia develop they persist indefinitely even after the drug is discontinued

ANSWER: D

Rationale:

Thiazide diuretics have well-established metabolic effects — the glucose intolerance mechanism involves thiazide-induced hypokalemia; potassium-dependent membrane depolarization in pancreatic beta cells triggers calcium influx and insulin exocytosis; hypokalemia impairs this depolarization, reducing insulin secretion and worsening glucose tolerance; thiazides also have direct effects raising LDL and triglycerides through incompletely characterized hepatic mechanisms; these effects are dose-dependent — lower doses (chlorthalidone 12.5 mg, HCTZ 12.5 mg) have smaller metabolic impact; correcting hypokalemia with supplementation or switching to a potassium-sparing combination may attenuate the glucose effect; metabolically neutral alternatives include ACE inhibitors, ARBs, and CCBs.

Option A: Option A is incorrect — thiazide metabolic effects are well-documented and dose-dependent; dismissing them as coincidental is pharmacologically incorrect.
Option C: Option C is incorrect — hydrochlorothiazide does not block proximal tubular glucose reabsorption; SGLT2 inhibitors work through this mechanism; thiazides act on the NCC in the distal convoluted tubule and do not cause glucosuria.
Option B: Option B is incorrect — thiazides do not inhibit HMG-CoA reductase; the lipid effects are through separate hepatic mechanisms; describing a reverse statin effect is pharmacologically incorrect.
Option E: Option E is incorrect — thiazide-induced metabolic effects are largely reversible upon dose reduction or discontinuation; they are not permanent.

6. A 47-year-old woman with hypertension, migraines, and Raynaud phenomenon has BP of 158/96 mmHg. She asks about antihypertensive options. Which of the following most accurately identifies the drug class that is both beneficial for her hypertension and specifically contraindicated or harmful for her Raynaud phenomenon?

A) ACE inhibitors are contraindicated in Raynaud phenomenon because bradykinin accumulation causes peripheral vasoconstriction that worsens digital ischemia during cold exposure
B) Dihydropyridine CCBs are contraindicated in Raynaud phenomenon because peripheral arteriolar dilation redistributes blood flow away from digital vessels through a steal mechanism
C) Non-selective beta-blockers worsen Raynaud phenomenon — beta-2 blockade in peripheral digital vessels reduces vasodilatory tone and can precipitate or worsen vasospastic attacks; dihydropyridine CCBs (particularly nifedipine and amlodipine) are in fact the treatment of choice for Raynaud phenomenon as they directly vasodilate peripheral arterioles and reduce vasospastic attacks; for this patient a dihydropyridine CCB addresses both hypertension and Raynaud, while beta-blockers should be avoided
D) Thiazide diuretics are specifically contraindicated in Raynaud phenomenon because volume contraction reduces peripheral perfusion pressure and worsens digital ischemia
E) ARBs are the drug of choice for Raynaud phenomenon because AT1 receptor blockade in digital vessels prevents angiotensin II-mediated vasospasm that is the primary trigger of Raynaud attacks

ANSWER: C

Rationale:

Non-selective beta-blockers worsen Raynaud phenomenon through beta-2 blockade in peripheral vascular smooth muscle — beta-2 receptors normally mediate vasodilation; their blockade reduces peripheral vasodilatory tone and can precipitate or worsen cold-induced vasospastic attacks in digital vessels; this is a recognized and clinically significant adverse effect; dihydropyridine CCBs are the pharmacological treatment of choice for Raynaud phenomenon — nifedipine (extended-release) and amlodipine directly vasodilate peripheral arterioles, reducing the frequency and severity of vasospastic attacks; for this patient with hypertension, migraines, and Raynaud phenomenon, a dihydropyridine CCB addresses all three conditions (BP control, some migraine benefit through vasodilation, Raynaud treatment).

Option A: Option A is incorrect — ACE inhibitors are not contraindicated in Raynaud; bradykinin accumulation causes vasodilation not vasoconstriction; some evidence suggests ACE inhibitors may actually benefit Raynaud through bradykinin-mediated vasodilation.
Option B: Option B is incorrect — dihydropyridine CCBs are the treatment of choice for Raynaud, not contraindicated; peripheral arteriolar dilation benefits digital perfusion and reduces vasospasm.
Option D: Option D is incorrect — thiazide diuretics are not specifically contraindicated in Raynaud; volume contraction does not cause clinically significant digital ischemia in typical Raynaud phenomenon.
Option E: Option E is incorrect — while losartan has some evidence for reducing Raynaud severity, ARBs are not the established drug of choice; dihydropyridine CCBs have the strongest evidence for Raynaud treatment.

7. A 65-year-old man with hypertension on amlodipine 10 mg and ramipril 10 mg develops a serum potassium of 6.2 mEq/L on routine labs. He has no symptoms. His eGFR is 44 mL/min. His ECG shows peaked T waves. Which of the following most accurately guides immediate management?

A) Reassure the patient and recheck potassium in 4 weeks — a potassium of 6.2 mEq/L with peaked T waves in an asymptomatic patient is a laboratory finding that does not require urgent intervention
B) Discontinue ramipril and initiate emergency intravenous calcium gluconate, insulin-dextrose, and sodium bicarbonate — all cases of hyperkalemia above 6.0 mEq/L require full emergency treatment regardless of ECG findings or symptoms
C) ECG changes (peaked T waves) at a potassium of 6.2 mEq/L indicate significant hyperkalemia with cardiac risk — immediate management priorities are: IV calcium gluconate to stabilize the myocardium, followed by measures to shift potassium intracellularly (insulin-dextrose, inhaled beta-2 agonists) and increase potassium elimination (loop diuretic, potassium binder such as patiromer or sodium zirconium cyclosilicate, or dialysis if renal function is severely impaired); ramipril should be held and the underlying cause addressed; reintroduction of RAAS inhibition at lower dose with a potassium binder may be possible once potassium is controlled
D) Administer oral sodium polystyrene sulfonate and recheck potassium in 48 hours — this is adequate management for any degree of hyperkalemia with ECG changes
E) The peaked T waves are a normal variant in a 65-year-old man and do not indicate cardiac risk — oral dietary potassium restriction alone is sufficient management for potassium of 6.2 mEq/L

ANSWER: C

Rationale:

Peaked T waves at K+ 6.2 mEq/L represent significant hyperkalemia with active cardiac toxicity requiring urgent treatment — the ECG changes indicate membrane instability that can progress to sine wave pattern, ventricular fibrillation, and cardiac arrest; the priority sequence is: IV calcium gluconate (stabilizes myocardial membrane within minutes without lowering potassium — buys time); then intracellular potassium shift with insulin-dextrose (onset 15–30 min) and inhaled beta-2 agonists (onset 30 min); then potassium elimination with loop diuretics if urine output adequate, patiromer or SZC (onset hours), or dialysis if severe renal failure; ramipril should be held; once stable, reintroduction of RAAS inhibition with a potassium binder may allow continued use of a drug with important indication.

Option A: Option A is incorrect — peaked T waves with K+ 6.2 mEq/L is a cardiac emergency; reassurance and 4-week recheck is inappropriate and potentially fatal.
Option B: Option B is incorrect — while urgent treatment is warranted, the statement that all K+ above 6.0 requires full IV emergency treatment regardless of ECG is an overstatement; ECG findings and clinical context guide treatment intensity; however in this case with peaked T waves, aggressive treatment is appropriate.
Option D: Option D is incorrect — sodium polystyrene sulfonate has a slow onset (hours) and significant GI side effect profile including intestinal necrosis; it is not recommended as monotherapy for hyperkalemia with ECG changes; modern binders (patiromer, SZC) are preferred and even these are adjunctive, not primary emergency treatment.
Option E: Option E is incorrect — peaked T waves at 6.2 mEq/L are not a normal variant; they represent hyperkalemia-induced cardiac membrane changes requiring urgent intervention.

8. A 58-year-old woman with hypertension is on valsartan 160 mg and chlorthalidone 25 mg with BP 138/84 mmHg. She is newly diagnosed with stage 3a CKD (eGFR 52) and albuminuria (ACR 380 mg/g). Her nephrologist suggests switching valsartan to an ACE inhibitor. Which of the following most accurately evaluates this recommendation?

A) Switching from an ARB to an ACE inhibitor is pharmacologically rational and necessary — ACE inhibitors are superior to ARBs for renoprotection in diabetic nephropathy and the switch will provide better CKD protection
B) Switch to an ACE inhibitor and add spironolactone simultaneously — triple RAAS blockade with ACE inhibitor plus ARB plus MRA provides the most complete RAAS suppression and best renoprotection
C) Adding an ACE inhibitor to the existing valsartan provides superior renoprotection through dual RAAS blockade and both should be continued simultaneously
D) Both ACE inhibitors and ARBs should be discontinued in stage 3a CKD — RAAS inhibition accelerates CKD progression at eGFR below 60 mL/min and neither class is appropriate at this stage
E) The switch is not pharmacologically necessary — ARBs and ACE inhibitors provide equivalent renoprotection in CKD with albuminuria through the same downstream mechanism of reducing intraglomerular pressure; valsartan should be continued at the current or higher dose; switching to an ACE inhibitor would be appropriate only if she develops intolerance to the ARB or if there is a specific indication for ACE inhibitor over ARB; adding a potassium binder to allow higher dose RAAS inhibition may be more beneficial than switching classes

ANSWER: E

Rationale:

ARBs and ACE inhibitors provide equivalent renoprotection through the same downstream mechanism — both reduce angiotensin II-mediated efferent arteriolar constriction, lowering intraglomerular pressure and reducing proteinuria; landmark trials with ARBs (RENAAL with losartan, IDNT with irbesartan) and ACE inhibitors (MICRO-HOPE with ramipril) demonstrate equivalent renoprotective benefit; switching classes without a specific reason (intolerance, side effect, compelling indication for one class) is not pharmacologically justified and creates unnecessary transition risk; continuing and potentially up-titrating valsartan, or adding a potassium binder to allow higher RAAS dose, would be more rational approaches to optimizing renoprotection.

Option A: Option A is incorrect — ACE inhibitors are not superior to ARBs for renoprotection; the evidence base is equivalent across the two classes; preference for one over the other is driven by tolerability (cough with ACE inhibitors) and specific trial populations, not efficacy.
Option C: Option C is incorrect — dual RAAS blockade with combined ACE inhibitor and ARB increases adverse events (hyperkalemia, AKI, hypotension) without additional renoprotective benefit, as demonstrated in the ONTARGET trial; this is not recommended.
Option D: Option D is incorrect — RAAS inhibition slows CKD progression in patients with albuminuria; discontinuing it at eGFR below 60 is not guideline-supported and would accelerate nephropathy progression.
Option B: Option B is incorrect — triple RAAS blockade with ACE inhibitor, ARB, and MRA simultaneously is not a guideline-recommended approach and carries prohibitive hyperkalemia risk; the ONTARGET data already showed dual ACE+ARB combination is harmful.

9. A 71-year-old man with hypertension, HFrEF (EF 32%), and symptomatic bradycardia (resting HR 48 bpm on bisoprolol 5 mg) has BP of 158/94 mmHg. His cardiologist wants to add an antihypertensive for better BP control but is concerned about further rate reduction. Which of the following most accurately guides additional antihypertensive selection?

A) Add amlodipine — dihydropyridine CCBs lower BP through peripheral vasodilation with minimal cardiac chronotropic or inotropic effect; amlodipine is safe in HFrEF (PRAISE trials) and does not lower heart rate, making it appropriate in a patient with symptomatic bradycardia on a beta-blocker
B) Add diltiazem — non-dihydropyridine CCBs provide excellent BP control and their negative chronotropic effect will actually help maintain a stable heart rate by preventing reflex tachycardia from BP reduction
C) Increase the bisoprolol dose — the bradycardia indicates the current dose is subtherapeutic and higher doses will provide both better rate control and BP reduction
D) Add verapamil — its combined negative chronotropic and vasodilatory effects provide superior BP reduction in HFrEF without the renal risks of RAAS inhibition
E) Add clonidine — central alpha-2 agonists lower BP without any cardiac chronotropic effect and are the safest antihypertensive addition in a patient with bradycardia and HFrEF

ANSWER: A

Rationale:

Amlodipine is the most appropriate addition — dihydropyridine CCBs lower BP through selective peripheral arteriolar vasodilation with minimal cardiac electrophysiological effects; amlodipine does not reduce heart rate and will not worsen the symptomatic bradycardia; it is specifically safe in HFrEF as demonstrated in the PRAISE-1 and PRAISE-2 trials; the combination of amlodipine with bisoprolol provides complementary BP lowering without additive chronotropic risk.

Option B: Option B is incorrect — diltiazem is a non-dihydropyridine CCB with significant AV nodal slowing effects; adding it to bisoprolol in a patient with symptomatic bradycardia at 48 bpm would risk severe symptomatic bradycardia, AV block, or cardiac arrest; additionally diltiazem is contraindicated in HFrEF due to negative inotropic effects.
Option C: Option C is incorrect — increasing bisoprolol in a patient with symptomatic bradycardia at 48 bpm is contraindicated; it would worsen the bradycardia and could cause hemodynamic compromise; the bradycardia signals that the current dose may already be excessive rather than subtherapeutic.
Option D: Option D is incorrect — verapamil is specifically contraindicated in HFrEF due to significant negative inotropy; it would worsen the cardiomyopathy and its AV nodal blocking effect would compound the bradycardia.
Option E: Option E is incorrect — clonidine does reduce heart rate through central sympatholysis and can worsen bradycardia; it is not the safest choice in a patient already at 48 bpm; its rebound hypertension risk with missed doses also makes it a suboptimal long-term agent in an elderly patient with HFrEF.

10. A 63-year-old woman with hypertension on lisinopril 20 mg, amlodipine 10 mg, and chlorthalidone 25 mg has BP of 156/94 mmHg despite confirmed adherence. Her potassium is 3.8 mEq/L and eGFR is 68 mL/min. She has no primary aldosteronism on workup. Which of the following most accurately describes the next pharmacological step for this truly resistant hypertension?

A) Double all three current medications simultaneously — full maximum doses of all three agents must be achieved before adding a fourth drug
B) Add hydralazine as the fourth agent — direct vasodilators are the guideline-recommended fourth-line therapy for resistant hypertension and hydralazine provides the most potent additional BP reduction
C) Add spironolactone 25–50 mg — the PATHWAY-2 trial demonstrated that spironolactone was the most effective add-on agent in resistant hypertension, superior to bisoprolol and doxazosin; even without confirmed primary aldosteronism, mineralocorticoid receptor antagonism provides significant additional BP reduction in resistant hypertension, likely through blocking aldosterone effects on sodium retention that persist despite three-drug therapy; her potassium of 3.8 mEq/L and eGFR of 68 provide adequate safety margin
D) Add a second ARB — combining lisinopril with an ARB provides dual RAAS blockade that is the most effective fourth agent in resistant hypertension
E) Refer for renal denervation — catheter-based renal sympathetic denervation is now the first-line fourth intervention before any additional pharmacological therapy in truly resistant hypertension

ANSWER: C

Rationale:

Spironolactone is the evidence-based fourth agent in true resistant hypertension — the PATHWAY-2 trial (Prevention And Treatment of Hypertension with Algorithm-guided therapy) randomized patients with resistant hypertension on three drugs to spironolactone, bisoprolol, doxazosin, or placebo and demonstrated that spironolactone produced the greatest additional BP reduction; the mechanism reflects excess aldosterone activity (even without overt primary aldosteronism) driving sodium retention that three-drug therapy fails to fully overcome; her potassium of 3.8 mEq/L and eGFR of 68 provide a safe starting point with close monitoring; dose starting at 25 mg with recheck of potassium and renal function in 2–4 weeks.

Option A: Option A is incorrect — all three agents are already at standard maximum doses; amlodipine 10 mg, lisinopril 20 mg, and chlorthalidone 25 mg are appropriate maximum doses; doubling them simultaneously is not guideline-supported and increases adverse event risk.
Option B: Option B is incorrect — hydralazine is not the guideline-recommended fourth agent in resistant hypertension; it causes reflex tachycardia, fluid retention, and has an inconvenient dosing schedule; spironolactone has superior evidence from PATHWAY-2.
Option D: Option D is incorrect — adding an ARB to lisinopril constitutes dual RAAS blockade, which increases hyperkalemia and AKI risk without additional BP or cardiovascular benefit as shown in ONTARGET; this combination is not recommended.
Option E: Option E is incorrect — renal denervation has evidence supporting its use but is not established as first-line before pharmacological options have been exhausted; spironolactone should be tried first given the strong PATHWAY-2 evidence.

11. A 56-year-old man with hypertension is started on lisinopril 10 mg. At 4 weeks his BP is 132/80 mmHg. His physician notes his potassium has risen from 4.1 to 4.8 mEq/L. He has no symptoms and his eGFR is stable at 72 mL/min. Which of the following most accurately describes the appropriate response to this potassium rise?

A) Discontinue lisinopril immediately — any potassium rise above 4.5 mEq/L on an ACE inhibitor indicates dangerous hyperkalemia that requires drug discontinuation regardless of symptoms or absolute value
B) Switch to an ARB — ARBs do not cause potassium rises because AT1 receptor blockade at the collecting duct is less complete than ACE inhibition making them safer for potassium homeostasis
C) Reduce the lisinopril dose to 5 mg — any potassium rise on an ACE inhibitor requires dose reduction regardless of the absolute potassium level or clinical context
D) Continue lisinopril unchanged — a potassium of 4.8 mEq/L is within the normal range (3.5–5.0 mEq/L) and represents an expected pharmacological effect of ACE inhibition through reduced aldosterone; no intervention is needed beyond routine monitoring at the next scheduled visit
E) Add a loop diuretic empirically to prevent potassium from rising further before it becomes dangerous

ANSWER: D

Rationale:

A potassium of 4.8 mEq/L is within the normal range and represents an expected, physiologically appropriate effect of ACE inhibition — reduced angiotensin II lowers aldosterone secretion, reducing collecting duct potassium excretion; a rise from 4.1 to 4.8 mEq/L is modest, expected, and clinically benign in a patient with stable renal function; no drug change or intervention is required; routine potassium monitoring at the next scheduled visit is appropriate; the threshold for concern is typically above 5.5 mEq/L, and the threshold for active management (dose reduction, dietary restriction, diuretic, or potassium binder) is generally above 5.5–6.0 mEq/L depending on trend and clinical context.

Option A: Option A is incorrect — potassium of 4.8 mEq/L is normal and does not require discontinuation; this level represents appropriate pharmacological effect and is not dangerous; discontinuing a well-tolerated effective antihypertensive for a normal potassium is inappropriate.
Option C: Option C is incorrect — dose reduction for a potassium within the normal range is not indicated; the clinical decision to reduce dose or discontinue is based on potassium above 5.5–6.0 mEq/L or clinical symptoms, not a rise within the normal range.
Option B: Option B is incorrect — ARBs cause equivalent potassium rises through the same downstream mechanism of aldosterone suppression; they are not safer for potassium homeostasis.
Option E: Option E is incorrect — empirically adding a loop diuretic to prevent expected normal potassium responses to ACE inhibition is unnecessary and risks volume depletion, electrolyte disturbance, and reflex RAAS activation.

12. A 44-year-old woman with hypertension is on chlorthalidone 25 mg with BP 134/82 mmHg. She is referred to endocrinology for secondary amenorrhea and elevated prolactin. Her workup reveals she is taking no other medications. Her endocrinologist asks the cardiologist whether chlorthalidone could be responsible. Which of the following most accurately addresses this question?

A) Chlorthalidone causes hyperprolactinemia through dopamine receptor antagonism in the pituitary — it is a known endocrine side effect of thiazide diuretics that causes secondary amenorrhea and galactorrhea
B) Chlorthalidone is not responsible — thiazide diuretics have no endocrine effects on prolactin secretion or the hypothalamic-pituitary axis; the elevated prolactin and amenorrhea require a separate workup for pituitary adenoma, hypothyroidism, or other causes
C) Chlorthalidone causes hyperprolactinemia through volume contraction-mediated stimulation of ADH release which cross-reacts with prolactin receptors in the anterior pituitary
D) Chlorthalidone raises prolactin through inhibition of renal dopamine production — reduced renal dopamine allows central dopaminergic tone to fall, disinhibiting prolactin secretion from lactotrophs
E) Chlorthalidone is responsible — all diuretics raise prolactin through osmoreceptor-mediated stimulation of the posterior pituitary which secondarily activates anterior pituitary lactotrophs

ANSWER: B

Rationale:

Thiazide diuretics do not cause hyperprolactinemia — chlorthalidone has no dopamine receptor antagonism and no established mechanism for raising prolactin; the elevated prolactin and secondary amenorrhea require a workup independent of the antihypertensive therapy; causes to evaluate include prolactinoma (most common), hypothyroidism (TRH stimulates prolactin), medications with dopamine antagonism (antipsychotics, metoclopramide, domperidone), pregnancy, renal failure, and physiological causes; the cardiologist should reassure the endocrinologist that chlorthalidone is not the culprit and the workup should proceed accordingly.

Option A: Option A is incorrect — thiazide diuretics do not antagonize dopamine receptors and do not cause hyperprolactinemia; dopamine receptor antagonism causing hyperprolactinemia is the mechanism of antipsychotics and certain antiemetics, not diuretics.
Option C: Option C is incorrect — ADH does not cross-react with prolactin receptors; volume contraction-mediated ADH release is a recognized thiazide effect but has no connection to prolactin secretion.
Option D: Option D is incorrect — renal dopamine production and central dopaminergic tone are not linked through this mechanism; this is a fabricated pathway not supported by pharmacology.
Option E: Option E is incorrect — osmoreceptor stimulation of the posterior pituitary affects ADH secretion, not prolactin; prolactin is secreted from anterior pituitary lactotrophs through a separate regulatory axis.

13. A 67-year-old man with hypertension and stable angina (last stress test 3 months ago showing mild fixed inferior defect, no ischemia on nuclear imaging) has BP of 162/96 mmHg and HR 88 bpm. He takes aspirin and atorvastatin. Which antihypertensive addresses both his hypertension and his angina most effectively?

A) Chlorthalidone — volume reduction lowers preload and reduces myocardial wall stress, providing antianginal benefit through a hemodynamic mechanism equivalent to beta-blockers
B) An ARB — AT1 receptor blockade in coronary vascular smooth muscle prevents angiotensin II-mediated coronary vasoconstriction that is the primary mechanism of stable angina
C) An ACE inhibitor — RAAS inhibition reduces afterload sufficiently to provide antianginal benefit equivalent to CCBs and beta-blockers in stable angina
D) Verapamil at maximum dose — non-dihydropyridine CCBs provide superior antianginal benefit over dihydropyridine CCBs because their negative chronotropic effect adds to the afterload reduction
E) A beta-blocker or a long-acting dihydropyridine CCB — both classes have established antianginal efficacy; beta-blockers reduce myocardial oxygen demand by lowering heart rate and contractility; long-acting dihydropyridine CCBs (amlodipine) reduce afterload and coronary vasospasm; either provides dual benefit for hypertension and stable angina; the choice depends on HR, LV function, and tolerability; his HR of 88 bpm makes a beta-blocker particularly appropriate to reduce demand ischemia

ANSWER: E

Rationale:

Beta-blockers and long-acting dihydropyridine CCBs are the two antihypertensive classes with established antianginal efficacy in stable angina — beta-blockers reduce heart rate and contractility, decreasing myocardial oxygen demand; they are particularly appropriate when HR is elevated (88 bpm here) as rate reduction directly reduces demand ischemia; amlodipine reduces afterload and prevents coronary vasospasm; both are guideline-recommended for stable angina; verapamil and diltiazem also have antianginal efficacy but require caution if LV function is impaired; the CAMELOT and PREVENT trials demonstrated that amlodipine reduced angina events in stable CAD.

Option A: Option A is incorrect — chlorthalidone does not have established antianginal efficacy; reducing preload does not provide the specific demand reduction or vasodilation of beta-blockers or CCBs in stable angina.
Option C: Option C is incorrect — ACE inhibitors do not have direct antianginal efficacy through the mechanism described; they reduce afterload but not to a degree that substitutes for beta-blockers or CCBs in symptomatic angina management.
Option D: Option D is incorrect — while verapamil has antianginal efficacy, it is not superior to dihydropyridine CCBs for all stable angina patients; its negative inotropic effect requires caution with LV dysfunction; framing it as the preferred agent is an overstatement.
Option B: Option B is incorrect — ARBs do not have established antianginal efficacy through AT1 blockade in coronary smooth muscle; coronary vasospasm as the primary mechanism of stable angina is pharmacologically incorrect; stable angina is typically caused by fixed atherosclerotic obstruction with demand ischemia.

14. A 59-year-old man with hypertension on metoprolol succinate 100 mg has BP 144/88 mmHg and HR 62 bpm. He is started on diltiazem 180 mg for rate control of newly diagnosed paroxysmal AF. Three days later he presents with symptomatic bradycardia (HR 38 bpm) and lightheadedness. His ECG shows second-degree AV block (Mobitz type I). Which of the following most accurately explains this adverse interaction?

A) Diltiazem competitively inhibits metoprolol metabolism at the CYP2D6 enzyme, raising metoprolol plasma levels tenfold and causing toxicity through pharmacokinetic drug interaction
B) The AV block is caused by diltiazem-induced hyperkalemia through calcium channel blockade in renal tubular cells impairing potassium excretion, with the elevated potassium directly suppressing AV nodal conduction
C) The bradycardia is caused by diltiazem-induced hypotension reducing coronary perfusion to the SA node, causing ischemic sinus node dysfunction
D) The interaction is pharmacokinetic — diltiazem inhibits P-glycoprotein efflux of metoprolol from cardiac myocytes, causing intracellular metoprolol accumulation that selectively poisons the AV node
E) The combination of metoprolol and diltiazem produces additive AV nodal suppression through complementary mechanisms — metoprolol blocks sympathetic beta-1 drive to the AV node reducing conduction velocity, while diltiazem blocks calcium-dependent AV nodal depolarization; together they produce excessive AV nodal suppression causing symptomatic bradycardia and second-degree AV block; both drugs must be held and supportive care provided; if AF rate control is still needed after recovery, the drugs must not be combined at these doses

ANSWER: E

Rationale:

This is a pharmacodynamic drug interaction — both metoprolol and diltiazem suppress AV nodal conduction through complementary mechanisms; metoprolol blocks sympathetic beta-1 adrenergic drive that normally enhances AV nodal conduction velocity and shortens the refractory period; diltiazem blocks L-type calcium channels in AV nodal cells, slowing the calcium-dependent phase 0 depolarization; together they produce additive AV nodal suppression that alone either drug at these doses might not cause; the result is symptomatic bradycardia and second-degree AV block requiring immediate discontinuation of both drugs and supportive care; this combination must be used with extreme caution if at all, particularly in elderly patients or those with baseline conduction abnormalities.

Option A: Option A is incorrect — while diltiazem does inhibit CYP3A4 (not CYP2D6, which metabolizes metoprolol), the primary mechanism of this interaction is pharmacodynamic AV nodal additive suppression, not pharmacokinetic metoprolol level elevation.
Option C: Option C is incorrect — diltiazem-induced hypotension causing SA node ischemia is not the mechanism; the AV block is a direct electrophysiological consequence of combined nodal suppression.
Option D: Option D is incorrect — P-glycoprotein inhibition causing intracellular metoprolol accumulation in cardiac myocytes is a fabricated mechanism not supported by pharmacology.
Option B: Option B is incorrect — diltiazem does not cause hyperkalemia through renal tubular calcium channel blockade; this is a fabricated mechanism; the AV block is directly caused by combined electrophysiological suppression.